Page last updated: 2024-12-10
narbomycin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
narbomycin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
narbomycin : A macrolide antibiotic that is narbonolide having a 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residue attached at position 6. It is biosynthesised by Streptomyces venezuelae. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5282036 |
| CHEMBL ID | 106096 |
| CHEBI ID | 29649 |
| SCHEMBL ID | 691770 |
| MeSH ID | M0056015 |
Synonyms (23)
| Synonym |
|---|
| 12-deoxypicromycin |
| narbomycin |
| C11998 , |
| 6036-25-5 |
| CHEMBL106096 , |
| chebi:29649 , |
| (3r,5r,6s,7s,9r,11e,13r,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-3,5,7,9,13-pentamethyl-1-oxacyclotetradec-11-ene-2,4,10-trione |
| AC1NQZE9 , |
| unii-024664144v |
| 024664144v , |
| (3r,5r,6s,7s,9r,11e,13r,14r)-14-ethyl-3,5,7,9,13-pentamethyl-2,4,10-trioxooxacyclotetradec-11-en-6-yl 3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranoside |
| SCHEMBL691770 |
| narbomycin [mi] |
| (+)-narbomycin |
| oxacyclotetradec-11-ene-2,4,10-trione, 14-ethyl-3,5,7,9,13-pentamethyl-6-((3,4,6-trideoxy-3-(dimethylamino)-.beta.-d-xylo-hexopyranosyl)oxy)-, (3r,5r,6s,7s,9r,11e,13r,14r)- |
| antibiotic b-62169b |
| (10e)-3-de((2,6-dideoxy-3-c-methyl-3-o-methyl-.alpha.-l-ribohexopyranosyl)oxy)-10,11-didehydro-10-demethyl-6,11,12-trideoxy-3-oxoerythromycin |
| erythromycin, 3-de((2,6-dideoxy-3-c-methyl-3-o-methyl-.alpha.-l-ribo-hexopyranosyl)oxy)-10,11-didehydro-10-demethyl-6,11,12-trideoxy-3-oxo-, (10e)- |
| picromycin, 12-deoxy- |
| surecn691770 |
| (3r,5r,6s,7s,9r,11e,13r,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-3,5,7,9,13-pentamethyl-1-oxacyclotetradec-11-ene-2,4,10-trione |
| Q27104078 |
| DTXSID301318396 |
Research Excerpts
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (3)
| Class | Description |
|---|---|
| macrolide antibiotic | A macrocyclic lactone with a ring of twelve or more members which exhibits antibiotic activity. |
| monosaccharide derivative | A carbohydrate derivative that is formally obtained from a monosaccharide. |
| enone | An alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (4)
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.92
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.92) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||